Study guide
15.2 Calciphylaxis & Radiation Tissue Injury
Certified Wound Specialist Physician CWSP
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the CWSP Exam
2 Chapter 1: Integumentary Anatomy & Wound Healing Biology
1.1 Skin Anatomy, Microstructure & Epidermal-Dermal Barrier Function 1.2 Acute vs Chronic Wound Healing Phases & Cellular Kinetics 1.3 Extracellular Matrix Composition, Collagen Architecture & MMP Regulation
3 Chapter 2: Musculoskeletal & Neurologic Anatomy
2.1 Musculoskeletal Anatomy of the Leg & Foot 2.2 Neuroanatomy & Nerve Physiology for Wound Care
4 Chapter 3: Cell Signaling, Biofilm & Barriers to Healing
3.1 Growth Factors, Cytokines & Angiogenic Pathways 3.2 Biofilm Microbiology, Quorum Sensing & Phenotypic Resistance 3.3 Cellular Senescence, Hypoxia & Inflammatory Arrest 3.4 Metabolic, Steroid & Nutritional Impairments in Wound Healing
5 Chapter 4: Patient Evaluation & Vascular Diagnostics
4.1 Comprehensive Patient & Periwound Physical Examination 4.2 Noninvasive Macrovascular Hemodynamics: ABI, TBI & Segmental Pressures 4.3 Microvascular Perfusion Diagnostics: TcPO2, SPP & Near-Infrared Spectroscopy 4.4 Diagnostic Angiography, Duplex Ultrasonography & Angiosome Concepts
6 Chapter 5: Pain, Risk, Functional & Nutrition Assessment
5.1 Wound Pain Assessment 5.2 Risk Assessment Tools & Risk Stratification 5.3 Functional & Cognitive Assessment 5.4 Nutrition Screening & Assessment
7 Chapter 6: Imaging, Biopsy, Atypical Wounds & Neuropathy
6.1 Musculoskeletal Imaging for Osteomyelitis & Deep Space Infections 6.2 Diagnostic Tissue Biopsy, Culture Techniques & Quantitative Microbiology 6.3 Diagnostic Differential of Atypical & Malignant Ulcerations 6.4 Comprehensive Diabetic Peripheral Neuropathy & Biomechanical Assessment
8 Chapter 7: Wound Bed Preparation, Debridement, Dressings & Topical Agents
7.1 TIME Principle & Wound Bed Preparation Framework 7.2 Surgical, Sharp, Enzymatic, Autolytic & Biosurgical Debridement Modalities 7.3 Advanced Wound Dressings, Exudate Control & Moisture Balance 7.4 Topical Agents: Antiseptics, Antibiotics & Active Topicals
9 Chapter 8: Cellular & Tissue-Based Products, NPWT & Hyperbaric Oxygen
8.1 Cellular, Acellular & Matrix-Like Advanced Biologics (CTPs) 8.2 Negative Pressure Wound Therapy (NPWT) & Instillation Protocols 8.3 Hyperbaric Oxygen Therapy (HBOT): Mechanisms, Indications & Safety
10 Chapter 9: Biophysical Technologies: Electrical Stimulation & Ultrasound
9.1 Electrical Stimulation for Wound Healing 9.2 Therapeutic Ultrasound in Wound Care
11 Chapter 10: Revascularization, Antimicrobial Stewardship & Offloading
10.1 Revascularization for Limb Salvage 10.2 Systemic Antimicrobial Stewardship & Deep Infection Management 10.3 Mechanical Offloading, Pressure Redistribution & Total Contact Casting
12 Chapter 11: Surgical Closure & Healing Complications
11.1 Surgical Closure, Skin Grafts, Flaps & Amputation Levels 11.2 Managing Complications: Bleeding, Allergy, Adverse Events & Scarring
13 Chapter 12: Nutrition Therapy & Case Review
12.1 Nutrition Therapy for Wound Healing 12.2 Case Review: Synthesizing Data, Outliers & Prognosis
14 Chapter 13: Diabetic & Ischemic Lower-Extremity Wounds
13.1 Diabetic Foot Ulcers: Pathophysiology, Staging & Limb Salvage 13.2 Peripheral Arterial Disease & Ischemic Extremity Ulcerations 13.3 Mixed Arterial-Venous Disease & Complex Diagnostic Dilemmas
15 Chapter 14: Venous Disease, Pressure Injuries, Lymphedema & Edema
14.1 Venous Leg Ulcers, Chronic Venous Insufficiency & Compression 14.2 Pressure Injuries: NPIAP Staging, DTPI & Prevention 14.3 Lymphedema, Phlebolymphedema & Complete Decongestive Therapy 14.4 Edema: Systemic vs. Local Causes
16 Chapter 15: Inflammatory, Calcific, Medication-Induced & Dermatologic Wounds
15.1 Autoimmune & Inflammatory Ulcerations: Pyoderma Gangrenosum & Vasculitis 15.2 Calciphylaxis & Radiation Tissue Injury 15.3 Medication-Induced & Hematologic Atypical Wounds 15.4 Dermatologic Conditions That Cause or Complicate Wounds
17 Chapter 16: Traumatic Wounds, Burns & Frostbite
16.1 Traumatic Wounds: Lacerations, Bites, Degloving & Open Fractures 16.2 Thermal Burns & Frostbite
18 Chapter 17: Surgical, Infectious & Pediatric Wounds
17.1 Surgical Wounds, Surgical Site Infection & Dehiscence 17.2 Infectious Causes of Wounds: Necrotizing, Mycobacterial, Fungal & Other Infections 17.3 Pediatric Wound Care
19 Chapter 18: Reimbursement, Regulation & Documentation
18.1 CPT Coding, Modifiers & Documentation for Debridement and Biologics 18.2 Regulatory Compliance, CMS Quality Programs & Hospital-Acquired Conditions 18.3 Documentation, Legal Concepts & Confidentiality
20 Chapter 19: Ethics, Adherence, Epidemiology & Evidence-Based Practice
19.1 Clinical Ethics, Informed Consent & Palliative Wound Management 19.2 Patient Adherence & Psychosocial Care 19.3 Epidemiology of Chronic Wounds 19.4 Research Literacy, Evidence-Based Medicine & Quality Improvement
15.2 Calciphylaxis & Radiation Tissue Injury
Key Takeaways Explain This Topic AI
Calciphylaxis (calcific uremic arteriolopathy) is a calcifying, thrombotic disease of small subcutaneous arterioles, mostly in patients on dialysis, with 1-year mortality often reported at 50% or higher; risk factors include female sex, obesity, diabetes, hyperphosphatemia, hypercalcemia, PTH extremes, hypoalbuminemia, and warfarin exposure.
Warfarin blocks vitamin K-dependent carboxylation of Matrix Gla Protein, a key inhibitor of vascular calcification, so warfarin should be stopped when safe once calciphylaxis is suspected.
When the diagnosis is uncertain, a deep punch or incisional biopsy into subcutaneous fat shows small-arteriole medial calcification, intimal hyperplasia, and microthrombi; treatment combines IV sodium thiosulfate (off-label, commonly 25 g three times weekly with dialysis), non-calcium binders, cinacalcet, lower dialysate calcium, pain control, and individualized debridement.
Osteoradionecrosis is exposed irradiated bone that fails to heal for at least 3 months without tumor recurrence; the Marx "3H" principle (hypovascular, hypocellular, hypoxic) explains it, and the classic Marx HBOT protocol uses 30 sessions at 2.4 ATA before resection and 10 after, although randomized evidence is mixed.
Last updated: September 2026
15.2 Calciphylaxis & Radiation Tissue Injury
Core Clinical Principle: Calcific uremic arteriolopathy (calciphylaxis) and late radiation tissue injury are both wounds of small-vessel failure: calcified, thrombosed subcutaneous arterioles in one, obliterative endarteritis in the other. Calciphylaxis carries 1-year mortality often reported at 50% or higher, and management centers on stopping triggers such as warfarin, correcting mineral metabolism, sodium thiosulfate, pain control, and careful wound care. Osteoradionecrosis is explained by the Marx hypovascular-hypocellular-hypoxic ("3H") principle, and hyperbaric oxygen is used selectively alongside surgical resection.
Both conditions punish aggressive, poorly planned surgery. Wound specialists must recognize them early, confirm the diagnosis when needed (biopsy for calciphylaxis when uncertain; biopsy to exclude recurrent tumor in irradiated tissue), and coordinate nephrology, oncology, surgery, and palliative care.
Calcific Uremic Arteriolopathy (Calciphylaxis / CUA)
Calcific Uremic Arteriolopathy (CUA) , commonly designated calciphylaxis , is a devastating small-vessel calcification syndrome characterized by progressive mural calcification, intimal fibroblastic hyperplasia, and endovascular microthrombus formation within small- to medium-sized dermal and subcutaneous arterioles (roughly 40 to 600 μm in diameter). The resulting downstream ischemia produces excruciatingly painful subcutaneous ischemic plaques, hemorrhagic necrosis, and extensive non-healing ulcerations. +-------------------------------------------------------------------------------------------------+
- | MOLECULAR & BIOCHEMICAL CASCADE OF CALCIPHYLAXIS |
- +-------------------------------------------------------------------------------------------------+
- | 1. CHRONIC KIDNEY DISEASE-MINERAL BONE DISORDER (CKD-MBD) |
- | • Hyperphosphatemia, hypercalcemia, and abnormal PTH (high or very low) promote calcification |
- | • Secondary Hyperparathyroidism -> Sustained parathyroid hormone (PTH) elevation |
- | • Systemic chronic inflammation (elevated IL-6, TNF-alpha) + Hypoalbuminemia |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 2. VASCULAR SMOOTH MUSCLE PHENOTYPIC TRANSDIFFERENTIATION |
- | • Elevated extracellular phosphate enters vascular smooth muscle cells (VSMCs) via Pit-1 |
- | • Upregulation of osteogenic transcription factors (Runx2 / Cbfa1, Msx2, Osterix) |
- | • VSMCs transform from contractile phenotype into bone-forming osteoblast-like cells |
- | • Secretion of extracellular matrix vesicles loaded with Calcium and Hydroxyapatite |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 3. LOSS OF ENDOGENOUS CALCIFICATION INHIBITORS (THE WARFARIN LINK) |
- | • Matrix Gla Protein (MGP) is a key local inhibitor of vascular calcification |
- | • MGP requires Vitamin K-dependent gamma-glutamyl carboxylation to become biologically active|
- | • WARFARIN inhibits Vitamin K Epoxide Reductase (VKOR) -> Accumulation of uncarboxylated MGP|
- | --> Weakened calcification defense -> Medial mineral deposition in small arterioles |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 4. ENDOVASCULAR OCCLUSION & ISCHEMIC PANNICULITIS |
- | • Concentric medial arteriolar calcification (40-600 μm vessels) + Subintimal fibroplasia |
- | • Endovascular fibrin thrombus formation -> Complete luminal microvascular occlusion |
- | • Subcutaneous fat ischemia -> Lobular panniculitis -> Stellate eschar & fatal sepsis risk |
- +-------------------------------------------------------------------------------------------------+
- Epidemiology & Lethality
Prevalence: CUA affects approximately 1% to 4% of the end-stage renal disease (ESRD) population, almost exclusively in patients undergoing chronic hemodialysis or peritoneal dialysis. Rare non-uremic calciphylaxis occurs in the setting of primary hyperparathyroidism, severe liver disease, rapid-weight-loss bariatric surgery, or malignancy.
Lethality: The clinical prognosis is dismal: 1-year mortality ranges from 50% to 80% . Sepsis from infected wounds is the leading cause of death secondary to bacterial colonization and deep infection of extensive, necrotic, ulcerated eschars.
Biochemical & Clinical Risk Factors
Hyperphosphatemia and Hypercalcemia: Persistent hyperphosphatemia and hypercalcemia (historically summarized as a high calcium-phosphate product) favor calcium-phosphate deposition in vessel walls, although many patients with calciphylaxis have normal values at diagnosis.
Parathyroid Hormone Extremes: Severe secondary hyperparathyroidism mobilizes calcium and phosphate from bone, and oversuppressed PTH with adynamic bone disease has also been linked to calciphylaxis.
Hypoalbuminemia: Serum albumin < 3.5 g/dL reflects malnutrition and chronic systemic inflammation, reducing the serum solubility of mineral complexes.
Female Sex & Obesity: Substantially higher prevalence in females (roughly twice as common in women in many series) and patients with a high body mass index ( B M I > 30 kg/m 2 BMI > 30\text{ kg/m}^2 BM I > 30 kg/m 2 ), driven by abundant subcutaneous adipose tissue containing dense arteriolar networks.
The Warfarin Mechanism: A Major Modifiable Risk Factor
Warfarin (Coumadin) is one of the most important modifiable risk factors for calciphylaxis.
Physiological Mechanism: Vascular calcification is actively restrained in healthy human tissue by Matrix Gla Protein (MGP) , a small, 84-amino acid protein synthesized by vascular smooth muscle cells and chondrocytes. MGP binds hydroxyapatite crystal nuclei and inhibits bone morphogenetic protein-2 (BMP-2), preventing soft-tissue and vascular wall mineralization.
Requirement for Vitamin K: To achieve biological activity, MGP must undergo post-translational gamma-glutamyl carboxylation catalyzed by gamma-glutamyl carboxylase, a process requiring reduced Vitamin K as an essential cofactor.
Warfarin Antagonism: Warfarin blocks Vitamin K epoxide reductase (VKOR), exhausting reduced Vitamin K reserves. Consequently, MGP remains in an inactive, uncarboxylated state ( ucMGP ). In the absence of functional carboxylated MGP, vascular calcification proceeds unchecked. In patients with ESRD who already possess a deranged calcium-phosphate milieu, warfarin exposure is strongly associated with developing CUA. ==================================================================================
- PRACTICE POINT: WARFARIN IN CALCIPHYLAXIS
- ==================================================================================
When calciphylaxis is suspected, stop warfarin whenever it is safe to do so.
- If anticoagulation remains necessary (e.g., high-risk atrial fibrillation or prior
- thromboembolism), consider a non-vitamin K alternative such as heparin or a
- direct oral anticoagulant chosen for kidney function; mechanical heart valves
need individualized cardiology input because DOACs are not an option.
- ==================================================================================
- Clinical Presentation & Anatomy
Prodromal Neuro-Ischemic Pain: Excruciating, unremitting, burning pain is the earliest and most prominent symptom, characteristically preceding visible cutaneous breakdown by several days to weeks. The pain is out of proportion to early physical findings.
Early Cutaneous Lesions: Deep-seated, indurated, tender subcutaneous plaques or nodules. Overlying skin displays a livedo reticularis or livedo racemosa pattern—an irregular, violaceous, net-like discoloration reflecting microvascular congestion.
Advanced Cutaneous Lesions: As endovascular thrombosis occludes the microcirculation, the plaques evolve into non-blanching violaceous purpura , hemorrhagic bullae, and focal cutaneous infarction. The center demarcates into a characteristic jagged, stellate, black, leathery, adherent eschar surrounded by an advancing violaceous ischemic rim.
Anatomical Distribution: CUA exhibits an overwhelming tropism for adiposity-rich anatomical regions : the anterior thighs, lower abdomen, buttocks, breasts, and calves. Distal acral forms (involving digits or toes) carry a somewhat lower mortality than proximal central lesions.
Diagnostic Biopsy: Deep Punch or Incisional Technique
While clinical presentation in an ESRD patient is often strongly suggestive, histological confirmation is the gold standard when diagnosis is uncertain:
Biopsy Protocol: Superficial punch biopsies often miss the diagnosis because calciphylaxis is a disease of subcutaneous arterioles. Sample with a deep punch biopsy or an incisional (wedge) biopsy that reaches well into the subcutaneous fat . Biopsy remains debated, because the site can ulcerate or become infected and a negative biopsy does not exclude the disease.
Histopathological Triad:
Concentric Medial Arteriolar Calcification: Microcalcification within the internal elastic lamina and tunica media of small subcutaneous arterioles (diameter roughly 40–600 μm).
Subintimal Fibroblastic Proliferation: Hyperplasia of subintimal myofibroblasts and endothelial swelling.
Endovascular Fibrin Thrombi: Luminal microthrombosis leading to downstream tissue infarction and ischemic lobular panniculitis (adipocyte necrosis with foamy macrophage infiltration).
Special Histochemical Stains: Calcification is confirmed on tissue sections using the Von Kossa stain (silver reduction demonstrating dense black calcium phosphate precipitates) or Alizarin Red stain (which stains calcium deposits bright orange-red).
Biopsy Risk: Performing a biopsy creates a mechanical skin defect that can itself fail to heal or become a nidus for fatal bacterial infection. Therefore, biopsy should be performed at the viable, indurated margin—never through the necrotic center—under sterile surgical technique.
Multimodal Medical Management of Calciphylaxis
No therapy has randomized-trial proof of benefit, so care relies on a coordinated multimodal plan spanning nephrology, wound care, dermatology, nutrition, and pain or palliative care: +-------------------------------------------------------------------------------------------------+
- | MULTIMODAL THERAPEUTIC REGIMEN FOR CALCIPHYLAXIS |
- +-------------------------------------------------------------------------------------------------+
- | 1. SODIUM THIOSULFATE (STS) INFUSION (Widely Used; Off-Label, Observational Evidence) |
- | • Dose: 25 grams IV (in 100 mL D5W or Normal Saline) administered over 30-60 minutes |
- | • Timing: During the final 30-60 minutes of hemodialysis, 3 times weekly (or post-dialysis) |
- | • Mechanisms: |
- | - Calcium Chelation: Proposed to form soluble calcium thiosulfate complexes that are |
- | more soluble than calcium phosphate and are cleared across the dialyzer membrane |
- | - Potent Antioxidant: Directly scavenges reactive oxygen species (ROS), reversing |
- | endothelial dysfunction and lipid peroxidation |
- | - Vasodilation: Promotes endogenous endothelial nitric oxide release, improving perfusion |
- | • Adverse Effects: High anion-gap metabolic acidosis, nausea/vomiting, volume overload |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 2. MINERAL & BONE METABOLISM NORMALIZATION |
- | • Calcimimetics: Oral Cinacalcet (Sensipar) to suppress parathyroid hormone (PTH) to |
- | KDIGO range (about 2 to 9 times the upper normal limit) without causing hypocalcemia |
- | • Phosphate Binders: Non-calcium, non-aluminum binders (Sevelamer carbonate, Lanthanum) |
- | --> Stop calcium-based binders (calcium acetate, calcium carbonate) |
- | • Low-Calcium Dialysate Bath: Lower dialysate calcium (commonly about 2.0 mEq/L) |
- | • Discontinue active Vitamin D analogs (calcitriol, paricalcitol) to prevent hypercalcemia |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 3. IATROGENIC TRIGGER REVERSAL & SURGICAL CONSIDERATIONS |
- | • Stop warfarin when safe; use a non-vitamin K anticoagulant if anticoagulation is needed |
- | • Aggressive Pain Control: Scheduled opioids, gabapentinoids, lidocaine infusions |
- | • Avoid Local Trauma: No subcutaneous injections (insulin, heparin) into indurated areas |
- | • DEBRIDEMENT: Individualize; many experts avoid aggressive excision of stable, dry |
- | eschar, while others debride to reduce infection risk; observational data are conflicting; |
- | keep stable eschar dry, use gentle methods, and remove infected or liquefied necrosis |
- | surgically when it drives sepsis |
- | • Hyperbaric Oxygen Therapy (HBOT): 2.0 to 2.4 ATA for 90 min (adjunct for refractory wounds)|
- +-------------------------------------------------------------------------------------------------+
- Radiation Necrosis & Osteoradionecrosis (ORN)
Therapeutic ionizing radiation delivers targeted cellular destruction to malignant neoplasms, but induces collateral, permanent microvascular and cellular damage to surrounding normal tissues. This chronic damage culminates in late radiation tissue injury (radiation necrosis) and osteoradionecrosis (ORN) .
Pathophysiology: The Marx "3H" Principle
Historically, osteoradionecrosis was viewed as a bacterial osteomyelitis. In 1983, Dr. Robert E. Marx proposed that radiation-induced bone and soft-tissue necrosis is primarily a non-healing wound of hypoxic, hypocellular, hypovascular tissue (the "3H" principle ), with microorganisms acting as contaminants rather than the cause. Newer models also emphasize radiation-induced fibrosis: +-------------------------------------------------------------------------------------------------+
- | THE MARX "3H" PRINCIPLE |
- +-------------------------------------------------------------------------------------------------+
- | 1. HYPOVASCULAR |
- | • Radiation generates free radicals -> Endothelial cellular DNA damage and senescence |
- | • Progressive obliterative endarteritis, subendothelial foam cell proliferation, thrombosis |
- | • Capillary dropout -> Massive permanent reduction in functional microvascular density |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 2. HYPOCELLULAR |
- | • Radiation induces apoptosis and irreversible cell cycle arrest in local parenchymal cells |
- | • Destruction of local osteoblasts, osteocytes, osteoclasts, and normal dermal fibroblasts |
- | • Emergence of senescent, radiation-induced myofibroblasts locked in dysfunctional fibrosis |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 3. HYPOXIC |
- | • Obliterative microvascular loss lowers tissue oxygen tension well below normal values |
- | • Severe, chronic tissue hypoxia arrests aerobic metabolism, halting macrophage phagocytosis |
- | and stopping normal fibroblast collagen synthesis and re-epithelialization |
- +-------------------------------------------------------------------------------------------------+
- Clinical Manifestations of Radiation Injury
Chronic Radiation Dermatitis: Poikiloderma (mottled hyperpigmentation and hypopigmentation, epidermal atrophy, and dense arborizing telangiectasias), dermal woody induration, loss of cutaneous appendages (alopecia, anhidrosis), and recurrent breakdown from minor mechanical shear.
Osteoradionecrosis (ORN): Exposed, non-healing, devitalized bone that persists for more than 3 months in a previously irradiated radiation field, in the absence of local recurrent malignancy. The most common site is the mandible following head and neck radiotherapy (radiation dose typically exceeding 60 to 70 Gy ), followed by the pelvic bones (sacrum, pubic symphysis) following pelvic radiation for cervical, prostate, or rectal carcinoma.
The Marx Hyperbaric Oxygen Protocol for Osteoradionecrosis
Because the underlying pathology is microvascular dropout, surgery in irradiated tissue heals poorly. Hyperbaric Oxygen Therapy (HBOT) acts as an angiogenic stimulus, establishing an oxygen gradient that stimulates vascular endothelial growth factor (VEGF), recruits circulating endothelial progenitor cells, and increases capillary density and tissue oxygen tension in irradiated tissue (in Marx's work, oxygen tension rose to roughly 80% of non-irradiated tissue values). Randomized evidence is mixed: a French multicenter trial of HBOT for established mandibular ORN (Annane et al., 2004) stopped early without showing benefit, and the HOPON trial (2019) did not show a clear benefit for preventing ORN after dental extractions, so indications are individualized. THE MARX HYPERBARIC OXYGEN PROTOCOL FOR ORN (STAGING & SCHEDULE)
==================================================================================
Marx Stage I ORN (Early bone exposure, responsive to HBOT):
• Initial HBOT: 30 sessions (dives) at 2.4 ATA for 90 minutes each (100% O2).
• Assessment: If soft tissue shows full resolution and bone heals, complete an
additional 10 post-treatment sessions (40 total dives).
Marx Stage II / Stage III ORN (Refractory, pathological fracture, or requiring resection):
• Pre-Operative HBOT: 30 sessions at 2.4 ATA for 90 minutes.
• Definitive Surgery: Radical resection of necrotic, non-bleeding bone to viable,
bleeding margins, with immediate or delayed vascularized free-tissue reconstruction.
• Post-Operative HBOT: 10 sessions at 2.4 ATA for 90 minutes post-operatively.
==================================================================================
The 30/10 schedule above follows the classic Marx staging protocol and the older 20/10 schedule is used before dental extraction in irradiated jaws; both remain widely taught even though trial results are mixed.